Akorn Reports Preliminary Fourth Quarter and Full Year 2014 Results
26 févr. 2015 07h00 HE
|
Akorn, Inc.
- Fourth Quarter GAAP EPS of $0.29; Non-GAAP Adjusted EPS of $0.50 -
- 2015 Revenue Guidance of Between $960 million and $980 million -
- 2015 Non-GAAP Adjusted EPS Guidance of $1.88 - $1.98 -...
Akorn Announces Fourth Quarter 2014 Earnings Release and Conference Call Information
29 janv. 2015 07h00 HE
|
Akorn, Inc.
LAKE FOREST, Ill., Jan. 29, 2015 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), expects to release fourth quarter 2014 earnings before the U.S. equities markets open on Thursday, February 26, 2015. In...
Akorn Receives FDA Approval for Phenylephrine HCl Ophthalmic Solution
20 janv. 2015 07h00 HE
|
Akorn, Inc.
LAKE FOREST, Ill., Jan. 20, 2015 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), today announced that it has received approval from the U.S. Food and Drug Administration (FDA) on the Company's New Drug...
Akorn Confirms Generic Durezol(R) Patent Challenge
15 janv. 2015 17h30 HE
|
Akorn, Inc.
LAKE FOREST, Ill., Jan. 15, 2015 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration...
Akorn to Present at the 33rd Annual J.P. Morgan Healthcare Conference
19 déc. 2014 09h30 HE
|
Akorn, Inc.
LAKE FOREST, Ill., Dec. 19, 2014 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a specialty generic pharmaceutical company, announced today that Raj Rai, Chief Executive Officer, will provide an...
Akorn Reports Preliminary 2014 Third Quarter Results
06 nov. 2014 07h30 HE
|
Akorn, Inc.
LAKE FOREST, Ill., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a niche pharmaceutical company, today reported preliminary financial results for the fiscal third quarter ended September...
Akorn, Inc. Announces Third Quarter 2014 Earnings Release and Conference Call Information
21 oct. 2014 11h02 HE
|
Akorn, Inc.
LAKE FOREST, Ill., Oct. 21, 2014 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX) will host a conference call on Thursday, November 6, 2014, to discuss third quarter 2014 results followed by a Q&A...
Akorn Acquires Xopenex(R) (levalbuterol HCI) Inhalation Solution From Sunovion
30 sept. 2014 16h15 HE
|
Akorn, Inc.
LAKE FOREST, Ill., Sept. 30, 2014 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a niche pharmaceutical company, today announced that it has signed a definitive agreement ("Agreement") to acquire...
Akorn Completes Acquisition of VersaPharm
12 août 2014 08h50 HE
|
Akorn, Inc.
LAKE FOREST, Ill., Aug. 12, 2014 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a niche pharmaceutical company, announced today that it has completed its previously announced acquisition of VPI...
Akorn Reports Preliminary 2014 Second Quarter Results
05 août 2014 06h05 HE
|
Akorn, Inc.
LAKE FOREST, Ill., Aug. 5, 2014 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a niche generic pharmaceutical company, today reported preliminary financial results for the second quarter ended...